Abingworth raises $465m for new life sciences fund Abingworth Bioventures 8
Oversubscribed transatlantic fund to invest in US, UK and European life science companies developing innovative therapeutics with potential to significantly improve human health
News provided by
Share this article
Share this article
LONDON, Feb. 3, 2021 /PRNewswire/ Abingworth, a leading international life sciences investment group, today announced the final closing of its latest transatlantic venture fund, Abingworth Bioventures 8 (ABV 8) at $465 million. ABV 8, which is Abingworth s 13
th life sciences fund, exceeded its target of $375 million and closed at its hard cap.
ABV 8 will target companies developing innovative therapeutics with potential to significantly improve human health. As with previous funds, ABV 8 will invest in opportunities in the US, UK and Continental Europe.
Share this article
Share this article
TOKYO and CAMBRIDGE, England, Jan. 12, 2021 /PRNewswire/ Sosei Group Corporation ( the Company ) (TSE: 4565) and PharmEnable, a UK drug discovery company, announce they have entered a collaboration to apply their respective technologies to drive novel drug discovery against a challenging G protein-couple receptor (GPCR) target associated with neurological diseases.
The collaboration will combine Sosei Heptares world-leading GPCR-focused structure-based drug design platform, which has fully structurally enabled the GPCR target, providing detailed structural insights and an assessment of tractability, with PharmEnable s proprietary advanced artificial intelligence (AI)-enabled and medicinal chemistry technologies (ChemUniverse and ChemSeek) to identify novel, highly specific drug leads for further development.
Sosei Heptares and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design
- Program focused on identifying small molecules that target a GPCR for degradation as potential therapeutic agents for gastrointestinal disorders
- Unique combination of novel technologies to enhance GPCR drug discovery and expand capabilities into wider drug target universe
News provided by
Share this article
Share this article
TOKYO and CAMBRIDGE, England, Dec. 22, 2020 /PRNewswire/ Sosei Group Corporation ( the Company ) (TSE: 4565), a world leader in GPCR-focused structure-based drug design and development, and Captor Therapeutics SA ( Captor ; Wroclaw, Poland and Allschwil, Switzerland), a European leader in targeted protein degradation, have entered a strategic technology collaboration focused on the discovery and development of novel small molecules that target the degradation of disease-associated G protein-coupled re
Nordic Nanovector - Financial Calendar 2021
Nordic Nanovector ASA (OSE: NANOV) provides an update for its Financial Calendar for 2021.
18 February 2021 - Quarterly Report - Q4 2020 / FY 2020
15 April 2021 - Annual General Meeting
26 May 2021 - Quarterly Report - Q1 2021
27 August 2021 - Quarterly Report - Q2 2021 / 1H 2021
18 November 2021 - Quarterly Report - Q3 2021
The dates are subject to change. The time and location of the presentations will be announced in due time.
This information is published pursuant to the requirements set out in the Continuing obligations.
For further information, please contact:
IR enquiries
Email: ir@nordicnanovector.com
Tel: +44 203 926 8535
Email: nordicnanovector@citigatedewerogerson.com
Sosei Heptares and GSK Enter Global Collaboration and License Agreement Targeting Immune Disorders of the Digestive System
- Single-target agreement focused on small molecule agonists of GPR35, a genetically validated target for inflammatory bowel disease and other gastrointestinal immune disorders
- Sosei Heptares eligible to receive an upfront payment, research funding and potential near-term development milestones of up to £34 million (US$44 million), potential downstream payments of up to £336 million (US$437 million) and tiered royalties
News provided by
Share this article
Share this article
TOKYO and CAMBRIDGE, England, Dec. 21, 2020 /PRNewswire/ Sosei Group Corporation ( the Company ) (TSE: 4565) announces it has entered into a global collaboration and license agreement with GlaxoSmithKline ( GSK )